Expertise in
5
conditions

Carlos A. Molina

Barcelona, CT, ES 
Expertise in
5
conditions
Barcelona, CT, ES 
OverviewLocationsClinical Research

Overview

Carlos Molina practices in Barcelona, Spain. Mr. Molina is highly rated in 5 conditions, according to our data. His top areas of expertise are Stroke, Transient Ischemic Attack (TIA), Carotid Artery Disease, Thrombectomy, and Embolectomy.

His clinical research consists of co-authoring 309 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Barcelona, CT, Spain
Other Locations
Zaragoza, AR, Spain
Granada, AN, Spain
Badalona, CT, Spain
Jaen, AN, Spain
Tarragona, CT 43007, Spain
Spain

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion
Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Thrombolysis With Low Dose Tenecteplase (TNK-tPA) Versus Standard of Care in Minor Ischemic Stroke With Proven Acute Symptomatic Occlusion
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drugs: Tenecteplase, Antiplatelet Monotherapy
Study Phase: Phase 3
EdoxabaN for IntraCranial Hemorrhage Survivors with Atrial Fibrillation (ENRICH-AF)
EdoxabaN for IntraCranial Hemorrhage Survivors with Atrial Fibrillation (ENRICH-AF)
Enrollment Status: Active_not_recruiting
Publish Date: January 16, 2025
Intervention Type: Drug, Other
Study Drug: Edoxaban
Study Phase: Phase 4
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial
Enrollment Status: Terminated
Publish Date: December 04, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 2 Less Clinical Trials

309 Total Publications

Correction to: PRERISK: A Personalized, Artificial Intelligence-Based and Statistically-Based Stroke Recurrence Predictor for Recurrent Stroke.
Correction to: PRERISK: A Personalized, Artificial Intelligence-Based and Statistically-Based Stroke Recurrence Predictor for Recurrent Stroke.
Journal: Stroke
Published: April 16, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Molina's expertise for a condition
ConditionClose
View All 20 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile